Congratulations to Bristol Myers Squibb for the FDA approval of Opdivo (nivolumab, a monoclonal antibody) in combination with the chemotherapies cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. Nivolumab is an IgG4 antibody that causes immune checkpoint blockade by diminishing inhibitory signaling through the programmed death receptor-1 pathway. ? Urothelial carcinoma is the most common type of bladder cancer. The chance that men will develop the cancer during their lifetime is approximately 1 in 28, while in women, the chance is about 1 in 89. ? Find the press release here ?? https://lnkd.in/dKmWyPTY ? #Biointron #Antibodies #Immunotherapy #PharmaNews #DrugDevelopment #FDA #Oncology #Healthcare #PD1 #Monoclonal #Chemotherapy
